News
September 5, 2006
Logical Therapeutics Inc. in-licenses novel anti-inflammatory drug
Logical Therapeutics, Inc. (Pittsburgh, PA) has entered into a licensing and collaboration agreement with Medinox, Inc. (Carlsbad, CA) for a novel non-steroidal anti-inflammatory agent (NSAID), to be known as LT-NS001.
LT-NS001 is a patented, orally active anti-inflammatory agent that has been shown to be as effective for treating pain and inflammation as the widely used NSAID, naproxen, in animal models. Furthermore, in animal models of NSAID-induced damage to the mucosal lining of the gastrointestinal tract, LT-NS001 was significantly less injurious than naproxen. LT-NS001 was evaluated in 47 subjects in a Phase I clinical trial. No serious adverse events were reported and no subjects were withdrawn from the study.
Logical Therapeutics intends to develop LT-NS001 for the treatment of mild to moderate inflammatory conditions, such as osteoarthritis (degenerative joint disease) and low back pain syndrome.
Under the terms of the deal, Logical Therapeutics has an exclusive license to develop and market LT-NS001 in North America, Europe and Australia. In return, Medinox will receive an upfront payment, and is eligible to receive future payments upon achievement of certain development and regulatory milestones, as well as royalties on sales.
About Medinox, Inc.
Medinox is a leader in nitric-oxide (“NO”) therapeutics and is developing a broad technology platform to address a wide variety of unmet medical needs including septic shock, acute respiratory distress syndrome (including SARS) and hemorrhagic shock. In addition to its NO technology, Medinox is also developing MX-1520, a unique therapeutic for sickle cell anemia. For information about Medinox and its products, please visit the Company's website at http://www.medinox.com, or contact Monte Lai, Ph.D., President & CEO of Medinox, Inc., at (760) 603-8989, or by email at cslai@medinox.com
About Logical Therapeutics, Inc.
Based in Waltham, MA, Logical Therapeutics, Inc. is a venture-backed, privately held biotechnology company focused on the development of products that treat diseases associated with inflammation. The company is developing a novel platform of bio-activated prodrugs, covered by an intellectual property portfolio. LT-NS001, a naproxen bio-activated prodrug, is the Company's lead compound, with additional NSAID prodrug candidates in development. Each program addresses unmet medical needs in multi-billion dollar markets. For more information on Logical Therapeutics, visit the company's website at www.logicaltx.com.
Please address inquiries regarding LT-NS001 to Logical Therapeutics' business development department at bd@logicaltx.com.
Contact Us
300 Second Avenue
Waltham, MA 02451
781.290.0900 phone
781.290.0911 fax
info@logicaltx.com